CGRP mAb Subcutaneous denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for cgrp mab subcutaneous are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies CGRP Monoclonal Antibodies for Medical Necessity

UnitedHealthcare's medical-necessity denials for subcutaneous CGRP monoclonal antibodies typically arise when the clinical record does not clearly document the severity and chronicity of migraine disease, or when the file lacks evidence that the patient has tried and failed the specific treatments UHC requires before approving this drug class. Reviewers apply UHC's published coverage determination criteria, which generally track the FDA-approved labeling and applicable neurology guidelines (such as those from the American Headache Society and the American Academy of Neurology). If your documentation does not map point-by-point to each criterion, the denial follows almost automatically — even when the medication is clinically appropriate.

## Why This Denial Is Appealable

A medical-necessity denial is an adverse benefit determination under your plan, giving you the right to a full internal appeal and, if that fails, an independent external review. Under ACA §2719 and its implementing regulations, non-grandfathered plans must provide external review through an accredited Independent Review Organization (IRO). ERISA §503 governs employer-sponsored plans and requires a full-and-fair review process. You generally have 180 days from the denial notice to file an internal appeal, and you can request an expedited review (typically resolved within 72 hours) if your condition is urgent.

## The Appeal Process

1. Request the full Explanation of Benefits (EOB) and a copy of UHC's Coverage Determination Guideline for this drug class — you are entitled to both under ERISA and ACA rules. 2. File a written internal appeal within the deadline stated on your denial letter. 3. If the internal appeal is upheld, request external review through the IRO assigned by UHC or your state insurance commissioner within the timeframe specified in the denial letter (typically 4 months from the final internal denial).

## Documentation to Gather

• Diagnosis confirmation: Neurologist or headache-specialist notes establishing the diagnosis, migraine frequency, and functional impairment over time.
• Prior-treatment history: A dated, outcomes-documented list of every preventive therapy previously tried, including how long each was trialed, why it was discontinued or deemed inadequate, and current treatment status.
• Clinical severity: Chart documentation of headache days per month, disability scores, and impact on daily functioning.
• Medical-necessity letter: A detailed letter from the prescribing physician explaining why this specific drug is necessary and why alternatives are insufficient.

## Criteria-Mapping Structure

Obtain the exact eligibility criteria from two sources: (a) the FDA-approved prescribing information for the specific CGRP monoclonal antibody prescribed, and (b) UHC's current Coverage Determination Guideline for this drug. Then build a two-column table: on the left, copy each requirement verbatim; on the right, cite the exact chart date and finding that satisfies it. Insurers reverse denials far more often when the appeal letter mirrors their own language and answers every requirement with a specific medical record citation.